÷°¡Á¦ | K2 EDTA |
---|---|
ÇØ´ç°Ë»ç | CBC, ABO, Rh, ABO Subtyping, Diff Count, Eosinophil Count, ESR, DAT,Du test, Reti, Malaria, HbAIc, PB morphology |
°Ëü·® | 3mL |
º¸°ü | ¿ë±â: ½Ç¿Â, äÇ÷ ÈÄ ³ÃÀå |
Âü°í»çÇ× | äÇ÷ ÈÄ Ç×ÀÀ°íÁ¦¿Í ÃæºÐÈ÷ È¥ÇÕ |
ÃֽŠ°Ë»çÇ׸ñ°ú °Ë»çÆгÎÀ» È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
°ËüÁ¾·ù |
EDTA tube |
|
---|---|---|
°Ëü·® | 3mL | |
°Ëüº¸°ü | ³ÃÀå | |
°Ëü¾ÈÁ¤¼º | ½Ç¿Â: 1ÀÏ ³ÃÀå: 7ÀÏ |
|
Âü°íÄ¡ | ||
ÀÓ»óÀûÀÇÀÇ | ¾Ë·ÎÇ»¸®³îÀº Åëdz °üÀý¿°ÀÇ Ä¡·áÁ¦·Î¼, µå¹® ºÎÀÛ¿ëÀ¸·Î ½ºÆ¼ºìÁ¸½¼ÁõÈıº(SJS)°ú µ¶¼ºÇ¥ÇDZ«»çÀ¶ÇØÁõ(TEN)°ú °°Àº ÁßÁõ ÇǺΠ¾à¹°ÀÌ»ó¹ÝÀÀ(severe cutaneous adverse drug reaction; SCAR)ÀÌ ³ªÅ¸³ª´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ´Â HLA-B À¯ÀüÀÚÀÇ ¿©·¯ À¯ÀüÇü Áß ÇϳªÀÎ *5801°ú °ü·ÃÀÌ ÀÖ´Ù. HLA-B*5801Àº Çѱ¹ÀÎÀÇ 5-10%¿¡¼ ¹ß°ßµÇ¸ç, ¾Ë·ÎÇ»¸®³î º¹¿ë ½Ã »ó±â ºÎÀÛ¿ëÀÌ ¹ß»ýÇÒ °¡´É¼ºÀÌ Å©°Ô Áõ°¡ÇϹǷΠ´ëü¾à¹° Åõ¿©°¡ °í·ÁµÇ¾î¾ß ÇÑ´Ù. ÀÌ °Ë»ç´Â HLA-B*5801 À¯ÀüÇüÀ» °áÁ¤ÇÏ´Â º¯À̸¦ PCR¹ýÀ¸·Î È®ÀÎÇϸç, ÇØ´ç º¯ÀÌ°¡ ¾øÀ¸¸é *5801ÀÌ ¾Æ´Ï¹Ç·Î ¾Ë·ÎÇ»¸®³îÀ» º¹¿ëÇÒ ¼ö ÀÖ´Ù. | |
ÁÖÀÇ»çÇ× | ||
Çʼö¼·ù | À¯ÀüÀڰ˻絿ÀǼºÐÀÚÀ¯Àü°Ë»çÀÇ·Ú¼ | |
ÃֽŰø¹® | ||
±Þ¿©±âÁØ | HLA-B5801 À¯ÀüÀÚÇü°Ë»çÀÇ ±Þ¿©±âÁØ ´©841´Ù Á¶Á÷Çü°Ë»ç-´ÜÀÏÇü-ÇÙ»êÁõÆø-(03)HLA-B5801, ´©841¶ó Á¶Á÷Çü°Ë»ç-´ÜÀÏÇü-¿°±â¼¿ºÐ¼®-(03)HLA-B5801Àº ¾Ë·ÎÇ»¸®³î ¾àÁ¦ Åõ¿©°¡ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô ´ÙÀ½°ú °°ÀÌ ¿ä¾ç±Þ¿©ÇÔ. - ´Ù À½ - 1. ÀÎÁ¤´ë»ó °¡. ¸¸¼º ½ÅÁúȯ ȯÀÚ·Î Åëdz Áø´Ü ÈÄ, °í´¢»êÇ÷ÁõÀÇ Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ì(uric acid °Ë»ç»ó 9mg/dLÀÌ»ó): ´©841´Ù Á¶Á÷Çü°Ë»ç-´ÜÀÏÇü-ÇÙ»êÁõÆø-(03)HLA-B5801 ¶Ç´Â ´©841¶ó Á¶Á÷Çü°Ë»ç-´ÜÀÏÇü-¿°±â¼¿ºÐ¼®-(03)HLA-B5801 ÀÎÁ¤ ³ª. »ó±â °¡.¿¡ ÇØ´çµÇÁö ¾Æ´ÏÇÑ °æ¿ì: ´©841´Ù Á¶Á÷Çü°Ë»ç-´ÜÀÏÇü-ÇÙ»êÁõÆø-(03)HLA-B5801 ÀÎÁ¤ 2. ÀÎÁ¤È½¼ö ¾Ë·ÎÇ»¸®³î ÃÖÃÊ Åõ¿© Àü 1ȸ (2021.8.1.½ÃÇà) |